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Abstract
Clinical benefit of ALK tyrosine kinase inhibitors (ALK-TKIs) in ALK-
rearranged lung cancer has been limited by the inevitable develop-
ment of acquired resistance, and bypass-molecular resistance
mechanisms remain poorly understood. We investigated a novel
therapeutic target through screening FDA-approved drugs in ALK-
TKI-resistant models. Cerivastatin, the rate-limiting enzyme inhibitor
of the mevalonate pathway, showed anti-cancer activity against
ALK-TKI resistance in vitro/in vivo, accompanied by cytoplasmic
retention and subsequent inactivation of transcriptional co-regu-
lator YAP. The marked induction of YAP-targeted oncogenes (EGFR,
AXL, CYR61, and TGFbR2) in resistant cells was abolished by cerivas-
tatin. YAP silencing suppressed tumor growth in resistant cells,
patient-derived xenografts, and EML4-ALK transgenic mice, whereas
YAP overexpression decreased the responsiveness of parental cells to
ALK inhibitor. In matched patient samples before/after ALK inhibitor
treatment, nuclear accumulation of YAP was mainly detected in
post-treatment samples. High expression of YAP in pretreatment
samples was correlated with poor response to ALK-TKIs. Our findings
highlight a crucial role of YAP in ALK-TKI resistance and provide a
rationale for targeting YAP as a potential treatment option for
ALK-rearranged patients with acquired resistance to ALK inhibitors.
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Introduction
Rearrangement of the anaplastic lymphoma kinase (ALK) gene
defines a distinct clinicopathologic subset of non-small cell lung
cancer (NSCLC) and occurs in approximately 3–7% of NSCLC cases,
with a higher prevalence among younger, never/light smoker, and
adenocarcinoma histology (Shaw et al, 2009). Crizotinib is currently
the standard first-line therapy for patients with advanced ALK-posi-
tive NSCLC (Solomon et al, 2014). However, most patients who
initially respond to crizotinib invariably relapse within 1 year due to
the emergence of drug resistance (Katayama et al, 2015). Recently,
more potent second-generation ALK tyrosine kinase inhibitors
(TKIs) have been developed for the treatment of crizotinib-resistant
and crizotinib-naı¨ve patients, but acquired resistance to these agents
is also an inevitable problem (Awad & Shaw, 2014). Based on
published reports, the mechanisms of resistance to ALK-TKIs
can be broadly classified as ALK-dependent alterations (e.g., ALK
secondary mutations and ALK gene amplification) and ALK-
independent alterations (e.g., upregulation of bypass signaling path-
ways; lineage changes; and drug efflux pump) (Katayama et al,
2012; Lin et al, 2017). ALK-dependent mechanisms generally indi-
cate continued dependency on ALK signaling and potential sensitiv-
ity to other ALK-TKIs, depending on the type of secondary
mutation. In a recent report by Gainor et al (2016), resistance muta-
tions were found in 20 and 50% of patients following treatment with
crizotinib and the second-generation ALK-TKIs (e.g., ceritinib and
alectinib), respectively. This indicates that at least half of patients
exhibit ALK-independent mechanisms upon acquisition of acquired
resistance to ALK-TKIs. Several examples of bypass signaling activa-
tion have been proposed (Crystal et al, 2014; Hrustanovic et al,
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2015), but major mechanisms to explain widespread emergence of
resistance are still unknown.
Yes-associated protein (YAP), a major downstream effector of
the Hippo pathway (Maugeri-Sacca` & De Maria, 2018), serves as
a transcriptional regulator by facilitating transcription of pro-
growth genes and suppressing pro-apoptotic genes. YAP has
emerged as a critical oncogene in multiple cancer types (Zan-
conato et al, 2016; Maugeri-Sacca` & De Maria, 2018). In particu-
lar, YAP has been reported to be closely associated with the
emergence of resistance to conventional chemotherapeutics
(Gujral & Kirschner, 2017) and BRAF/MEK/EGFR-targeted thera-
pies (Lin et al, 2015; Lee et al, 2018). However, only a few stud-
ies have verified the clinical relevance of YAP activation in
human samples.
The mevalonate (MVA) pathway is an essential metabolic
pathway that produces sterols and isoprenoids that are essential
for tumor growth and progression (Mullen et al, 2016). MVA
pathway metabolite isoprenoids, such as farnesyl pyrophosphate
(FPP) and geranylgeranyl pyrophosphate (GGPP), are necessary
for the post-translational prenylation of small GTPases that play
a significant role in multiple intracellular signaling pathways. A
number of studies have shown that statins, which inhibit the
rate-limiting enzyme of the MVA pathway, 3-hydroxy-3-methyl-
glutaryl-CoA reductase (HMGCR), exhibit anti-cancer effects in
many cancers by reducing isoprenoids (Yu et al, 2018). Notably,
GGPP has recently been found to activate YAP by inhibiting its
phosphorylation and promoting its nuclear accumulation. With
this mechanism, statins as antagonists of isoprenylation can
inhibit YAP nuclear localization and transcriptional responses,
leading to growth arrest and apoptosis of cancer cells (Zhao
et al, 2008; Zhang et al, 2009; Sorrentino et al, 2014; Wang et al,
2014; Mi et al, 2015).
This study aims to identify novel resistance mechanisms to ALK-
TKIs by utilizing high-throughput screening using a library of FDA-
approved drugs composed of a collection of 640 clinically used
compounds with known and well-characterized bioactivity, safety,
and bioavailability. Here, we report a previously unidentified
YAP-mediated mechanism of acquired resistance to crizotinib in
ALK-positive NSCLC using in vitro and in vivo models with subse-
quent validation in patient samples before and/or after ALK inhi-
bitor therapy. Ultimately, our findings provide a novel promising
therapeutic strategy targeting YAP signaling to overcome acquired
resistance to ALK-TKIs in ALK-positive NSCLC.
Results
Statins exhibit in vitro and in vivo anti-cancer activity against
crizotinib-resistant cells
We generated crizotinib-resistant cells (CR cells; CR pool, CR #1
and CR #3) as described in the Materials and Methods. These CR
cells exhibited lower phosphorylated and total ALK levels
concomitant with morphological changes from round to fibrob-
last-like cells compared with that of parental cells (Appendix Fig
S1A–C). Silencing ALK using small interfering RNA (siRNA)
transfection and ALK inhibitors ceritinib and lorlatinib had no
effect on the growth of CR cells (Appendix Fig S1D and E).
Moreover, sequencing of the ALK tyrosine kinase domain of
resistant cells showed no secondary ALK mutations. Altogether,
CR cells were unlikely to have arisen by ALK-dependent mecha-
nisms.
To uncover novel signaling pathways related to crizotinib-
acquired resistance, we screened a 640 FDA-approved drug library
for drug efficacy in parental and CR pool cells. The average
z-score was calculated for drug effect on cell viability. Cerivas-
tatin was the most selective hit for CR pool cells compared with
parental cells, and further confirmed a greater decrement in cell
viability of other CR cells (CR #1 and CR #3; Fig 1A–C). Consid-
ering that cerivastatin was withdrawn from the market in 2001
due to fatal rhabdomyolysis and kidney failure (Furberg & Pitt,
2001), we additionally evaluated the anti-proliferative capability
of the other clinically available statins, atorvastatin and simvas-
tatin, in CR cells. Although they were used at higher concentra-
tions than cerivastatin, these statins successfully inhibited cell
growth at the concentration range reported in other previous
preclinical studies (Fig EV1A and Appendix Fig S2A). Cerivastatin,
simvastatin, and atorvastatin remarkably increased the expression
levels of c-PARP, c-Cas3, and p21 in CR cells (Fig EV1B, and
Appendix Fig S2B). These in vitro findings were further confirmed
by in vivo xenograft studies showing that cerivastatin and ator-
vastatin significantly delayed tumor growth of the CR pool
(Figs 1D and EV1C). Based on the anti-cancer effects of statins,
cerivastatin with the lowest IC50 was used as a representative in
subsequent experiments despite being a clinically discontinued
drug.
Statins are a class of cholesterol-lowering drugs that reduce
cardiovascular diseases by blocking HMGCR, a rate-controlling
enzyme of the MVA pathway (Appendix Fig S3) (Mullen et al,
2016; Iannelli et al, 2018). Among the important metabolites of
the MVA pathway, the addition of MVA and GGPP was able to
rescue cerivastatin-induced cell growth inhibition in CR cells,
whereas FPP and squalene had no effect (Fig 1E). Addition of
GGPP markedly abrogated cerivastatin- and atorvastatin-induced
c-PARP, c-Cas3, and p21 expression in CR pool, but not in
parental cells (Figs 1F and EV1D). Conversely, geranylgeranyl-
transferase I inhibitor GGTI-298 was able to reproduce the effects
of statin by increasing the expression of c-PARP, c-Cas3, and p21
in CR cells in a dose-dependent manner (Fig 1F). However, farne-
syl transferase inhibitor FTI-277 only weakly increased p21
expression and we failed to detect c-PARP and c-Cas3 levels
(Appendix Fig S4).
Reportedly, the MVA pathway is associated with mutant p53
expression in a variety of cancer types (Freed-Pastor et al, 2012;
Sorrentino et al, 2014; Parrales et al, 2016; Turrell et al, 2017).
However, there was no difference in the p53 mutational status
between H3122 parental and resistant cells (Appendix Table S1).
These results suggest that anti-cancer activity of statin in resistant
cells may be independent of TP53 mutation.
Cerivastatin decreases upregulation of multiple oncogenic
factors by inactivating YAP
Given that the MVA-GGPP axis is involved in cancer progression
by activating the transcriptional co-regulator YAP as a Hippo
pathway downstream effector (Zhao et al, 2008; Zhang et al,
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◀ Figure 1. In vitro and in vivo anti-cancer activity of cerivastatin against CR cells.A Z-scores for FDA-approved compounds on cell viability of parental (black circle) and CR pool (red triangle) cells.
B Top 20 list of identified hits in the screen of FDA-approved drugs.
C Cell viability curves of parental and CR cells in response to combined treatment with cerivastatin and crizotinib (n = 3).
D Tumor growth curves of parental (n = 3) and CR pool xenografts (n = 6) treated with the indicated drugs (Kruskal–Wallis with Dunn’s post hoc test: **P < 0.01 vs.
vehicle, ##P < 0.01 vs. crizotinib treatment. ns, not significant).
E Bar chart showing cell viability of cells after cerivastatin treatment in the presence and absence of metabolites of the mevalonate pathway. MVA: mevalonic acid
(0.5 mM), GGPP: geranylgeranyl pyrophosphate (10 lM), FPP: farnesyl pyrophosphate (10 lM), squalene (10 lM; ANOVA with Tukey’s post hoc test: *P < 0.05,
**P < 0.01 vs. control in each cell. #P < 0.05, ##P < 0.01 vs. the value at the indicated comparison in each cell; n = 4).
F Representative immunoblots of the indicated proteins in cells treated with cerivastatin (1 lM) alone or with GGPP (10 lM) for 24 h (left) and in lysates of cells
treated with GGTI-298 for 24 h (right). Blots are representative of three independent experiments.
Data information: Data represent means  SD (C and D) or  SEM (E).
Source data are available online for this figure.
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2009; Sorrentino et al, 2014; Wang et al, 2014; Mi et al, 2015),
we investigated the relevance of the YAP signaling pathway in crizo-
tinib resistance. Figure 2A showed that CR pool cells exhibited a
lower level of basal YAP phosphorylation and a significant nuclear
accumulation of YAP compared with that of parental cells, indicating
an increase in the transcriptional activity of YAP. Treatment with
cerivastatin and atorvastatin (Figs 2A and EV1E) resulted in a robust
increase in YAP phosphorylation and translocation of nuclear YAP
into the cytoplasm, which was reversed by the addition of GGPP.
Despite depletion of endogenous expression of the Hippo pathway
core component LATS1/2 by siRNA, moreover, YAP was still phos-
phorylated upon treatment with cerivastatin, and dephosphorylated
after the addition of GGPP (Appendix Fig S5). These results suggest
that cerivastatin inhibits GGPP-mediated YAP activation in a Hippo
pathway-independent manner.
Next, we found that the CR pool cells exhibit a significant upreg-
ulation of YAP target gene signature compared with that of parental
cells (Fig 2B and Appendix Fig S6). Based on functional enrichment
analysis, interaction network analysis between YAP and genes
belonging to the top 15 signaling pathways including metabolic
pathway, focal adhesion, cytoskeleton pathways, and Ras signaling
demonstrated that a number of genes were functionally connected
to YAP (Fig 2C). In particular, we focused on EGFR, AXL, and
TGFbR2, which are known to be involved in drug resistance
(Miyawaki et al, 2017; Yun et al, 2018), as well as CYR61, which is
a direct YAP target. Upregulation of these genes in CR pool cells was
confirmed by Western blot analysis (Fig 2D). We also found that
the expression levels of vimentin (VIM), cyclin D1, insulin-like
growth factor-binding protein 3 (IGFBP3), and the MAPK phos-
phatase DUSP6 varied depending on the CR clones, indicating
heterogeneity in the resistant clones (Appendix Fig S7A). YAP inhi-
bition with siRNAs markedly suppressed the expression of EGFR,
AXL, TGFbR2, and CYR61, but had no effect on expression levels of
the epithelial-to-mesenchymal transition (EMT)-associated gene
VIM and tumor suppressor genes IGFBP3 and DUSP6 (Fig 2E and
Appendix Fig S7B). Verteporfin (VP), a pharmacological inhibitor of
YAP, is known to inhibit YAP transcriptional activity by preventing
the interaction of YAP and TEA domain family members (Liu-Chit-
tenden et al, 2012; Yu et al, 2014). Treatment with VP, cerivastatin,
or GGTI-298 also showed similar results (Fig 2F). Given that YAP
and its paralogue transcriptional co-activator with PDZ-binding
motif (TAZ) are known to be functionally redundant and similarly
regulated by Hippo signaling (Zhang et al, 2009; Moroishi et al,
2015), we further determined the role of TAZ in our system. Unlike
YAP, TAZ knockdown did not affect the expression of EGFR, AXL,
and TGFbR2, but robustly inhibited CYR61 and VIM expression and
increased IGFBP3 expression (Fig EV2 and Appendix Fig S7). These
results suggest that there are potential differences between YAP and
TAZ in the context of ALK-TKI resistance.
YAP activation promotes resistance to ALK-TKI in vitro and
in vivo
We next examined whether YAP, the target of cerivastatin identi-
fied from the drug screen, is a novel target of ALK resistance. To
this end, we established the following three stable cell lines from
H3122 cell line: (i) endogenous YAP-expressing pLVX cell line as
control, (ii) YAP-WT cell line overexpressing wild-type YAP, and
(iii) YAP-S127A cell line overexpressing constitutively active YAP.
Immunoblot analysis demonstrated that YAP was successfully
overexpressed in both YAP-WT and YAP-S127A cells. Phosphory-
lated levels of YAP in YAP-S127A cells were the lowest among
the three stable cell lines (Fig EV3A). YAP-WT and YAP-S127A
cells exhibited markedly reduced susceptibility to crizotinib
concomitant with upregulation of CYR61, EGFR, and AXL expres-
sion (Fig EV3A and B).
To clarify the functional role of YAP in ALK-TKI resistance
in vivo, pLVX, YAP-WT, and YAP-S127A cells were injected subcuta-
neously into nude mice. Tumor xenografts derived from YAP-WT
and YAP-S127A cells grew faster than those from pLVX cells. On day
21 of tumor growth, tumor volumes of the YAP-S127A xenograft
were the largest, indicating a potential role of active YAP on tumor
progression (Fig 3A). Consistent with the in vitro findings, anti-
tumor efficacy of crizotinib was remarkably reduced in both YAP-
WT and YAP-S127A tumors. Treatment with cerivastatin signifi-
cantly suppressed tumor growth in YAP-WT (P < 0.05 vs. vehicle)
and YAP-S127A xenografts (P < 0.05 vs. vehicle), but not in pLVX
xenograft (Fig 3B). Notably, the combined treatment of cerivastatin
and crizotinib produced a potent anti-tumor synergy compared with
that of crizotinib (P < 0.05) or cerivastatin alone (P < 0.05) in YAP-
WT xenograft. Interestingly, YAP-S127A xenograft was less respon-
sive to cerivastatin compared with YAP-WT xenograft. Moreover,
combining of cerivastatin with crizotinib was comparable to the
effect of single-agent treatment. These results may imply a limited
inhibitory effect of cerivastatin on artificial YAP activity because
YAP-S127A is not due to GGPP-mediated YAP activity. In line with
▸Figure 2. GGPP-mediated yes-associated protein (YAP) activation.A Left: representative immunoblots for the indicated proteins in lysates of cells treated with cerivastatin (1 lM) alone or with GGPP (10 lM) for 24 h. Middle:
immunofluorescent staining of YAP (red) and DAPI (blue) in cells treated with the method described on the left. Right: representative immunoblots for the indicated
proteins in nucleus/cytoplasm fractionation of cells treated with the same conditions as on the left.
B Microarray analysis heat-map showing a published YAP signature in CR pool cells compared with parental cells (P < 0.05 and fold change > 1.5-fold). The data set
is provided in Table EV1.
C Interaction network analysis between YAP and genes belonging to the top 15 categories using the Cytoscape program. Major neighbor genes that are connected
with YAP are highlighted in circle. The red circle refers to upregulated genes, and the green circle refers to downregulated genes.
D, E Representative immunoblots of the indicated proteins in basal lysates of CR cells compared with parental cells (D) and in lysates of CR cells transfected with either
negative control siRNA (Con si) or YAP siRNAs (two sets of siRNAs against YAP: YAP si#1 and YAP si#2) (E).
F Representative immunoblots of the indicated proteins in CR cells after treatment of VP, cerivastatin, or GGTI-298 for 24 h.
Data information: Blots are representative of three independent experiments.
Source data are available online for this figure.
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these results, upon combination of cerivastatin and crizotinib, over-
all expression and nuclear localization of YAP were completely
suppressed in tumor sections of YAP-WT, but nuclear YAP subpopu-
lation was still detected in that of YAP-S127A (Fig 3C). Taken
together, although both YAP overexpression and activation are
responsible for resistance to crizotinib, transcriptional activity of
YAP may be more aggressive and play a critical role in tumor
progression.
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Figure 3. Effect of yes-associated protein (YAP) overexpression on the response to crizotinib.
A Left: representative images showing tumorigenesis of nude mice implanted with pLVX (left flank) and YAP-WT or YAP-S127A (right flank) stable cells. Middle:
representative images of IHC of YAP in sections from the indicated xenograft tumor. Right: comparison of xenograft tumor volumes after 3 weeks from when tumor
volume reached 40–50 mm3 on the left. ***P < 0.001 vs. the value on day 0 in each group. #P < 0.05, ###P < 0.001 vs. the value for the indicated comparison
§§P < 0.01 vs. the value on day 21 in YAP-WT. ns, not significant.
B Tumor growth curves of pLVX, YAP-WT, and YAP-S127A xenografts during treatment with crizotinib (50 mg/kg), cerivastatin (1 mg/kg), or a combination of the two.
*P < 0.05, **P < 0.01 treatment group vs. vehicle in each xenograft. #P < 0.05, ##P < 0.01, §P < 0.05 vs. the value for the indicated comparison. ns, not significant.
C Representative IHC images of YAP staining in tumor sections from mice treated as indicated. The red arrow indicates YAP staining.
Data information: Data represent means  SD (A and B). Kruskal–Wallis with Dunn’s post hoc test was used for comparing multiple groups.
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Inhibition of YAP overcomes tumor sensitivity to ALK-TKIs in
mouse xenografts, patient-derived xenograft models, and
EML4-ALK transgenic mice
The average z-score of YAP short hairpin RNA (shRNA) was higher
than that of other genes in shRNA screen of 1,000 genes on the
survival of multiple ALK-TKI-resistant patient-derived cells (PDCs)
in publicly available data sets (Dardaei et al, 2018; Appendix Fig S8),
supporting our findings that YAP is closely associated with ALK-TKI
resistance. To verify the potential of YAP as a promising target over-
coming resistance to ALK-TKI, we evaluated the effect of YAP inhibi-
tion by siRNA/shRNA in ALK-TKI-acquired-resistant in vitro/in vivo
models. YAP silencing markedly reduced the proliferation and clono-
genicity of CR cells mainly due to cell cycle arrest at G0/G1 phase
with induction of p21 expression, which was slightly enhanced in co-
treatment with crizotinib (Figs 4A and B, and EV4). Similar results
were obtained with ceritinib-acquired-resistant cells (LR pool and LR
#6) displaying higher expression of YAP and YAP target genes
compared with that of parental cells (Appendix Fig S9). In contrast,
TAZ silencing failed to attenuate the clonogenicity of resistant cells,
except for CR #3 cells (Appendix Figs S9 and S10). In xenograft
models, following subcutaneous cell injection, tumors from control
cell were mostly observed within 2 weeks, but those from stable
YAP knockdown cells began to appear in about 1 month and were
consequently smaller at the end of the experiment (Fig 4C). In line
with results, a YAP pharmacological inhibitor VP treatment yielded
superior tumor growth inhibition (TGI) compared with vehicle in CR
pool xenograft (Fig 4D). Considering that VP has been clinically used
as a photosensitizer in photodynamic therapy (Bressler & Bressler,
2000; Battaglia Parodi et al, 2016), our results showed that VP exhi-
bits significant therapeutic effects against ALK-TKI resistance by
inhibiting YAP transcriptional activity without light activation, which
is consistent with other reports (Brodowska et al, 2014; Slemmons
et al, 2015; Cheng et al, 2016; Ma et al, 2016). The in vivo activity of
YAP inhibition was further validated in crizotinib-acquired-resistant
patient-derived xenograft (PDX) models (YHIM-1001CR) exhibiting
predominant nuclear accumulation of YAP protein (Fig 5A and
Appendix Fig S12). Figure 5B showed a significant nuclear accumu-
lation and overexpression of YAP in progressive disease (PD) on
crizotinib or ceritinib compared with control in EML4-ALK transgenic
mouse model. Following PD on ceritinib treatment, combined treat-
ment with ceritinib and VP led to pronounced tumor shrinkage and
complete remission after 2 weeks, whereas continued treatment with
ceritinib alone led to further growth of the lung nodules (Fig 5C).
Taken together, these results demonstrate that targeting YAP is a
potential therapeutic option for resistance of ALK-TKIs in vitro and
in vivo.
Clinical implications of nuclear YAP expression in tumor biopsies
from patients with ALK rearrangement
To explore the clinical relevance of our findings, we assessed the
expression pattern of YAP in tumor biopsies acquired before and/or
after ALK inhibitor therapy from 17 ALK-positive patients (Table 1).
All 17 patients had been treated with ALK inhibitors (crizotinib or
ceritinib), and both pre- and post-treatment samples were available
for nine of these patients. The intensity of overall YAP expression was
not significantly different between pre- and post-treatment tumors,
but nuclear YAP staining was more prominent in post-treatment
tumors compared with pretreatment tumors (Fig 6A and B). Next, to
determine whether the degree of YAP expression is associated with
poor prognosis, the origin patients of tumor biopsies were classified
into partial response (PR) and stable disease (SD)/PD groups accord-
ing to the best response to ALK-TKI, after which YAP staining inten-
sity was compared between pretreatment tumor biopsies of the two
groups (Fig 6C). Of the 10 PR patients, 9 (90%) showed a staining
intensity score of 1 (low) to 2 (intermediate) for YAP. On the other
hand, of 5 SD/PD patients, 3 (60%) showed a staining intensity score
of 3 (high) for YAP. These results indicate that high YAP expression
may affect efficacy to ALK inhibitors. Meanwhile, we then investi-
gated genetic mutation status of the seven biopsy samples available
by targeted sequencing (Fig EV5, Table EV2, and Appendix Table S2)
and found no genetic alterations in YAP itself or in its signaling path-
way. Only 1 sample (14.3%) revealed an L1196M mutation (Awad &
Shaw, 2014; Gainor et al, 2016), which is the most commonly known
ALK secondary mutation, and showed relatively low YAP expression.
Moreover, several TP53 mutations (P33R, E247G, R174Q, or L155R)
were detected in our patient samples, but they are not well-known
hot spots of TP53. Collectively, these findings strongly suggest that
YAP activation may serve as a clinical biomarker of resistance to
ALK-TKI independent of genetic alterations.
Discussion
In this study, we identified for the first time the activation of YAP as
a potential therapeutic target for overcoming acquired resistance to
ALK-TKI in ALK-rearranged NSCLC using cell lines, mouse models,
▸Figure 4. Effect of yes-associated protein (YAP) knockdown on cell growth and tumor growth in vitro and in vivo.A Colony formation of the indicated cells treated with either dimethyl sulfoxide or crizotinib 24 h after siRNA transfection. Top: representative images for crystal violet
staining. Bottom: quantification for crystal violet staining. **P < 0.001 vs. DMSO in Consi, #P < 0.05, ##P < 0.01 vs. the value at the indicated comparison in each cell
lines. n = 3.
B Top: representative immunoblots of total YAP levels in stably selected CR pool cells after infection with either negative control shRNA (Con sh) or YAP shRNA (YAP sh).
Bottom: colony formation following treatment with either dimethyl sulfoxide or crizotinib in CR pool cells stably expressing Con sh or YAP sh.
C Left: tumor growth curves of xenografts derived from CR pool cells stably expressing Con sh or YAP sh. **P < 0.01 vs. Con shRNA Middle: representative images
showing tumorigenesis of Con sh (left flank) or YAP sh (right flank) stable CR pool cells implanted to nude mice. Right: comparison of the xenograft tumor volumes
after 3 weeks from when tumor volumes reached 40–50 mm3 on the left. ***P < 0.001 vs. the value on day 0 in each group. ##P < 0.01 vs. the value for the
indicated comparison. ns, not significant. n = 6.
D Tumor growth curves of CR pool cell-derived xenografts during treatment with the indicated drugs. **P < 0.01 vs. vehicle. ##P < 0.01 vs. crizotinib treatment. ns, not
significant. n = 6.
Data information: Data represent means  SD (A, C and D). Kruskal–Wallis with Dunn’s post hoc test was used for comparing multiple groups.
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and patient samples. Our findings also demonstrated that statins
control transcriptional activity of YAP in geranylgeranylation-depen-
dent manner, ultimately impacting the survival of resistant cells by
modulating the expression of YAP-targeted oncogenic factors. This
study proposes a preclinical rationale that targeting YAP may be a
promising strategy for the treatment of ALK-TKI-resistant NSCLC.
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The mechanisms of acquired resistance to ALK-TKIs have been
studied extensively using diverse experimental platforms and
approaches. In particular, activation of EGFR (Katayama et al, 2012;
Miyawaki et al, 2017), reactivation of the GTPase RAS–MAPK
pathway (Crystal et al, 2014; Hrustanovic et al, 2015), and pheno-
typic changes such as EMT (Gainor et al, 2016; Wei et al, 2018)
have been consistently reported in ALK-TKI-resistant models lacking
secondary ALK alterations. Moreover, we and others have reported
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Figure 5. Therapeutic activity of a combined treatment of crizotinib with either cerivastatin or VP in ALK-tyrosine kinase inhibitors-resistant ALK-positive
patient-derived xenograft models and EML4-ALK transgenic mice.
A Left: representative IHC images of yes-associated protein (YAP) staining in tumor sections from YHIM1001 and YHIM1001CR. Right: individual tumor volumes of
YHIM-1001CR xenografts treated with the indicated drugs. The red arrow indicates YAP staining.
B Representative images of hematoxylin and eosin (H&E) and IHC staining of YAP in the indicated tumor sections from EML4-ALK transgenic mice.
C Representative MRI images of two treatment groups (75 mg/kg ceritinib [C] and 75 mg/kg ceritinib + 10 mg/kg VP [C + VP]) with mice showing PD under ceritinib
treatment. The yellow arrow indicates lung tumor nodules.
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that AXL overexpression in an EMT phenotypic context is implicated
as a mechanism of resistance to ALK-TKIs (Yun et al, 2018). Consis-
tent with these reports, in present crizotinib-resistant in vitro models
with cross-resistance to other ALK-TKIs, the expression of multiple
targetable candidates such as EGFR, AXL, and CYR61 was concur-
rently increased, and expression levels of DUSP6 and IGFBP-3 were
suppressed (Fig 2B–D and Appendix Fig S7A). Therefore, given
these diverse resistance mechanisms, it is necessary to identify a
master regulator of drug resistance to effectively overcome resis-
tance to ALK-TKIs.
The Hippo signaling pathway is one of the 10 oncogenic signal-
ing pathways with frequent genetic alterations, and Hippo path-
way genes such as LATS1/2 and YAP were somatically mutated
in 10% of 9,125 tumors across 33 cancers profiled by The Cancer
Genome Atlas (Sanchez-Vega et al, 2018). YAP has recently been
recognized as a key determinant that mediates drug resistance by
acting in parallel to other signaling pathways (Lin et al, 2015;
Gujral & Kirschner, 2017; Lee et al, 2018). Of note, overexpression
of YAP and its target gene signatures has been reported to be
associated with poor clinical outcomes in NSCLC patients (Wang
et al, 2010). In line with previous reports, we demonstrated that a
number of genes belonging to enriched pathways in crizotinib-
resistant cells are functionally associated with YAP (Fig 2B and C
and Appendix Fig S6). YAP silencing markedly diminished the
expression of EGFR, AXL, and CYR61, suggesting a potential role
of YAP in orchestrating multiple bypass signaling activation to
ALK inhibition (Fig 2E). YAP knockdown also upregulated expres-
sion of the cyclin-dependent kinase inhibitor p21, resulting in a
marked induction of cell cycle arrest at G0/G1 phase, thereby
suppressing tumor cell proliferation of in vitro/in vivo-resistant
models (Figs 4 and EV4, and Appendix Fig S9). More importantly,
YAP inhibition led to successful synergy in acquired-resistant
ALK-positive PDX models and EML4-ALK transgenic mouse model
against ALK-TKIs (Fig 5). Conversely, ectopic expression of YAP
led to an incomplete response to crizotinib in ALK-positive
in vitro/in vivo models accompanied with induction of CYR61,
EGFR, and AXL (Figs 3 and EV3). Although some genes
mentioned above have already been reported as YAP target genes
(Zhao et al, 2008), the association between YAP transcriptional
activity and resistance to ALK-TKI in ALK-rearranged NSCLC has
not been reported. Our argument is strongly supported by our
findings showing prominent nuclear YAP expression in ALK-TKI-
resistant tumors compared with pretreatment tumors in ALK-rear-
ranged NSCLC patients (Fig 6). We also observed a tendency
toward high YAP expression in pretreatment specimens among
non-responders (SD or PD) to ALK inhibitors than among respon-
ders, highlighting the capability of YAP as a survival input for
ALK-rearranged NSCLC. A recent study on resistance to ALK inhi-
bitors in multiple ALK inhibitor-resistant PDCs has revealed that
inhibition of Src homology phosphotyrosine phosphatase 2 (SHP2)
restores sensitivity to ALK inhibitors (Dardaei et al, 2018). Inter-
estingly, several lines of evidence indicated that SHP2 interacts
with the YAP/TAZ complex and that this interaction is essential
for the oncogenic function of SHP2 (Kim et al, 2018). Thus, these
previous findings potentiate our theory that YAP may serve as a
central mediator of ALK-TKI resistance.
Growing evidence suggests that TAZ promotes resistance to
various anti-cancer therapies including cytotoxic chemotherapy
(Moroishi et al, 2015; Zhan et al, 2018; Liu et al, 2019). However,
our results showed that TAZ knockdown had no inhibitory effect on
Table 1. Expression pattern of yes-associated protein (YAP) in pre- and post-ALK tyrosine kinase inhibitors paired samples (n = 17).
Patients Treatment
Duration of
treatment
(month)
Best response
to ALK
inhibitor
ALK secondary
mutation
(post-treatment)
YAPscore Nuclear YAP-positive
Pre Post Pre (%) Post (%)
1 Ceritinib 8 SD NA 1 NA 0 NA
2 Crizotinib 13 PR NA 2 2 50 80
3 Crizotinib 16 PR None 2 3 20 80
4 Ceritinib 6 SD None 3 NA 50 NA
5 Ceritinib 10 PR None 2 NA 40 NA
6 Crizotinib 14 PR NA 1 NA 20 NA
7 Ceritinib 2 PD None 3 NA 0 NA
8 Crizotinib 22 SD None 2 2 30 30
9 Crizotinib 10 PR L1196M NA 2 NA 60
10 Crizotinib 7 PR None 1 2 0 10
11 Crizotinib 13 SD NA 3 3 20 70
12 Crizotinib 17 PR NA 3 3 10 50
13 Crizotinib 9 PR NA 2 3 30 30
14 Crizotinib 13 PR NA 2 3 50 80
15 Crizotinib 17 PR NA 2 NA 10 NA
16 Crizotinib 27 SD NA NA 3 NA 80
17 Crizotinib 11 PR NA 1 2 10 60
NA, not available tissue; PD, progressive disease; PR, partial response; SD, stable disease.
10 of 17 EMBO Molecular Medicine 11: e10581 | 2019 ª 2019 The Authors
EMBO Molecular Medicine Mi Ran Yun et al
the clonogenicity of CR and LR cells (Fig 4A and Appendix Figs S9
and S10). Interestingly, TAZ knockdown resulted in a marked
increase in tumor suppressor IGFBP3 expression and complete inhi-
bition of EMT-associated VIM expression, but YAP did not influence
the expression of these genes (Appendix Fig S7). These results raise
the possibility that TAZ may, at least in part, be associated with
ALK-TKI resistance through distinct transcriptional events. Indeed,
several studies have shown that YAP and TAZ regulate different
downstream target genes by tissue-specific or cell type-specific tran-
scription factor-binding partners (Varelas et al, 2008; Zhang et al,
2009). Moreover, Mi et al (2015) have reported that YAP mainly
contributes to cell proliferation, while TAZ appears to regulate
migration in breast cancer. Therefore, it is necessary to further
investigate the functional role of TAZ in ALK-TKI resistance.
It is well known that inhibition of the MVA pathway by statins
impairs oncogenic functions of YAP/TAZ in a variety of cancer
types (Sorrentino et al, 2014; Wang et al, 2014; Mi et al, 2015;
Mullen et al, 2016). Here, we also showed anti-cancer activity of
statins in resistant preclinical models by reducing nuclear localiza-
tion and transcriptional activity of YAP (Figs 1 and EV1, and
Appendix Fig S2). Notably, statin-mediated regulation of YAP
target gene expression required GGPP, but was largely independent
of MST/LATS kinase activity. In this regard, statins may represent
effective therapeutic drugs against ALK-TKI resistance. In addition
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Figure 6. IHC analysis of yes-associated protein (YAP) expression in pre- and post-treatment tumor biopsies from patients with ALK rearrangement.
A Representative IHC images of YAP staining in pretreatment (pre-tyrosine kinase inhibitor [TKI], n = 15) and post-treatment (post-TKI, n = 11) tumor biopsies from
patients treated with ALK-TKI (n = 26).
B Quantification of YAP IHC staining intensity (left) and YAP nuclear localization (right) based on IHC staining. Scoring was determined by calculating the sum of
distribution scores and intensity scores as described in Materials and Methods. Each symbol represents individual tumor biopsies. Data represent means  SD.
P-values were determined using the Mann–Whitney test.
C Quantification of YAP expression according to the response criteria in pretreatment tumor biopsies. PR: partial response (n = 10), SD/PD: stable disease/progressive
disease (n = 5).
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to the preclinical anti-cancer effects of statin (Yang et al, 2017;
Gordon et al, 2018), large-scale epidemiological studies have
demonstrated the beneficial effects of long-standing statin use on
lowering the risk of mortality of patients in diverse cancer types
(Goss et al, 2016; Hung et al, 2017; Seckl et al, 2017). Although
the clinical use of statins as anti-cancer agents may be limited due
to undefined dosage/schedule and potential toxicity at micromolar
concentrations (Holstein et al, 2006), the development of agents
targeting the MVA pathway should be further explored considering
the key role of MVA pathway metabolites in oncogenic activities
of YAP.
In conclusion, MVA pathway-mediated YAP/TAZ activation
converges to modulate key oncogenic processes, which are essential
for driving resistance to ALK-TKI in ALK-rearranged NSCLC, and
statin inhibits tumor growth and cell survival of ALK-TKI-resistant
models by targeting YAP transcriptional activity. These findings
indicate the need to develop YAP-targeting therapeutic agents to
overcome acquired resistance to ALK-TKI in ALK-rearranged
NSCLC.
Materials and Methods
Chemicals
Crizotinib, ceritinib, and lorlatinib were purchased from Selleck
Chemical (Houston, TX). The library of FDA-approved drugs
(Screen-Well FDA-Approved Drug Library, 640 chemical compounds
dissolved at 10 mM in dimethyl sulfoxide) was obtained from Enzo
Life Sciences (Plymouth Meeting, PA). The following compounds
were purchased from Sigma Chemical Co. (St. Louis, MO): cerivas-
tatin, simvastatin, fluvastatin, atorvastatin, GGPP, FPP, squalene,
GGTI-298, FTI-277, and verteporfin. Drug preparation and use of all
reagents were conducted according to manufacturer’s instructions.
Generation of ALK-TKI-resistant cells
H3122 cells were kindly provided by Dr Okamato from Kyushu
University (Fukuoka, Japan). Cells were cultured in RPMI-1640
(Sigma-Aldrich) supplemented with 10% fetal bovine serum and
1% penicillin/streptomycin at 37°C in 5% CO2, and the media were
exchanged every 2–3 days. To generate crizotinib (CR)-/ceritinib
(LDK, LR)-acquired-resistant models, we followed previously
described protocols (Yun et al, 2018). Resistant cells (CR pool and
LR pool; bulks of each drug-resistant cells, #1–10; independently
derived resistant clones in colonies expanded from each pool) were
derived after approximately 6 months of culture in the continuous
presence of 1 lM crizotinib or ceritinib. CR pool, CR #1, CR #3, LR
pool, and LR #6 resistant cells were used in all experiments.
Cell viability assay
Cells were seeded onto 96-well plates (1 × 103/well) and, after an
overnight attachment period, were exposed to the various concen-
trations of appropriate drugs for 72 h. Cell viability was analyzed
using Cell Titer Glo (Promega) according to manufacturer’s proto-
col. The survival curves were calculated by Prism 5 software. For
colony formation assays, siRNA-transfected single cells were seeded
onto 6-well plates (3 × 103/well) and, after an overnight attachment
period, were exposed to the appropriate drugs for 7 days. Media
including the corresponding concentration of drugs were replaced
every 3 days. Upon treatment completion, cells were washed with
phosphate-buffered saline (PBS), fixed in 4% paraformaldehyde for
10 min, and stained with 0.5% crystal violet for 20 min. To evalu-
ate clonogenicity, images were captured using flatbed scanner and
then the cells were dissolved with 20% SDS. The OD of the colony
formation was read at 570 nm using a SpectraMax 250 microplate
reader (Molecular Devices).
Sanger sequencing
Genomic DNA was extracted from parental and resistant cells by
the DNeasy Blood & Tissue Kit (Qiagen, Hilden, Germany) accord-
ing to manufacturer’s instructions. The entire ALK kinase domain
was sequenced by Sanger dideoxynucleotide sequencing, and the
entire coding region of the TP53 gene was sequenced using One-
click Sanger Sequencing (Macrogen Inc, South Korea). Sequencing
data were analyzed with Geneious v11.1.5 and NCBI BLAST. Using
previously published reports (Rivlin et al, 2011; Freed-Pastor et al,
2012; Sorrentino et al, 2014; Parrales et al, 2016; Turrell et al,
2017), we listed 42 hot spots of TP53, including R270H mutation
associated with the MVA pathway and then verified their
presence in tested cell lines. Primer sequences are listed in
Appendix Table S3.
Immunofluorescence
Cells were washed with TBS, fixed with 4% paraformaldehyde for
30 min, permeabilized with 0.1% Triton X-100 for 10 min, and
incubated with blocking solution (2% BSA in 0.1% Triton X-100 in
TBS) for 30 min. The cells were then sequentially labeled with
primary antibodies and the appropriate secondary antibodies diluted
in blocking solution. The cells were mounted using prolong gold
antifade reagent with DAPI and evaluated by a laser scanning confo-
cal microscopy (LSM 510; Carl Zeiss, Jena).
Immunoblot analysis
Cell lysates containing equal amounts of protein were separated by
SDS–PAGE, transferred to membrane (Hybond; Amersham Bios-
ciences, Piscataway, NJ), and immunoblotted with specific primary
and secondary antibodies. The blots were detected by SuperSignalTM
West Pico Chemiluminescent Substrate (Thermo Fisher Scientific,
MA). The membrane was re-blotted with an anti-b-actin antibody as
an internal control. Band intensities were quantified using an Alpha
View SA (Cell Biosciences, Santa Clara, CA). For cell fractionation,
the cells were centrifuged at 300 g for 5 min, and the pellets were
suspended in hypotonic buffer for 15 min on ice. Lysates were
centrifuged at 14,000 g for 30 s at 4°C, and the resultant super-
natants (cytosolic fraction) were transferred to new tubes. The
resultant pellets were suspended in extraction buffer and shaken at
4°C for 30 min on a shaking platform at 150 rpm. The nuclear
extracts were centrifuged at 14,000 g for 10 min at 4°C, and the
resultant supernatants (nuclear fractions) were frozen (70°C).
Lamin A/C was used as a nuclear marker and tubulin as a cytoplas-
mic marker.
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Flow cytometry
To analyze cell cycle distribution, after appropriate drug treatment,
both adherent and floating cells were harvested and fixed in cold
70% ethanol at 4°C for 4 h. The fixed cells were centrifuged at 300 g
for 5 min, and the cell pellet was washed twice with ice-cold PBS
and stained with 50 lg/ml propidium iodide (Sigma) solution
containing 10 lg/ml RNase A. Cell cycle distribution was evaluated
from 10,000 cells using a FACSVerse (BD Biosciences, CA, USA)
running FlowJo V10.0.6 software.
siRNA transfections
Small interfering RNA transfections were performed with Lipofec-
tamineTM RNAiMAX (Invitrogen, Carlsbad, CA) in antibiotic-free
medium according to the manufacturer’s instructions. Interference
efficiency of the siRNA on target gene expression was evaluated by
Western blot. Specific siRNAs for ALK (IDs: HSS105340 and
HSS105342), YAP (IDs: HSS115944 and HSS115942), and SilencerTM
Select Negative Control (#4390843) were obtained from Thermo
Fisher Scientific (MA, USA). Specific siRNAs for TAZ (siGENOME
WWTR1 #2, 4; MQ-016083-00-0002), LATS1 (E-004632-00-0020),
LATS2 (E-003865-00-0020), and Accell Non-targeting pool (D-
001910-10-20) were purchased from GE Dharmacon (Lafayette, CO).
Microarray analysis
Total RNA was hybridized to GeneChip Human Gene 2.0 ST Arrays
(Affymetrix, Santa Clara, CA) according to the manufacturer’s
instructions. Data analysis was performed using Affymetrix
Expression ConsoleTM software. The resulting data are publically
available via Gene Expression Omnibus accession GSE117181. Dif-
ferentially expressed genes (DEGs) identified by using local pooled
error test using R-based Bioconductor. Heat-maps were plotted
using Morpheus (https://software.broadinstitute.org/morpheus/)
and were generated based on a corrected P-value of < 0.05 and a
fold change of > 1.5. Gene sets for YAP were obtained from previ-
ously published gene signature (Zhao et al, 2008; Zhang et al,
2009). Pathway analysis of DEGs with the P-value < 0.05 was
performed in the Search Tool for the Retrieval of Interacting Genes
(STRING; http://www.string-db.org) using the Kyoto Encyclopedia
of Genes and Genomes (KEGG) pathway. q-value was controlled for
multiple testing by determining the false discovery rate. A difference
was considered significant if the q-value was < 0.05. To construct
the network of genes belonging to TOP 15 KEGG pathway cate-
gories, including YAP gene, these genes were imported into the
STRING and only interactions with a combined score of > 0.7 were
pasted into the Cytoscape (http://www.cytoscape.org) plugin to
create the network visualization.
Plasmid construction and site-directed mutagenesis
pBABE-YAP1 plasmid DNA (15682) was purchased from Addgene
(Cambridge, MA). The YAP S127A mutant construct (serine to
alanine at residue 127) was generated by the introduction of a single
point mutation to pBABE-YAP1 using QuikChange Site-Directed PCR
Mutagenesis Kit (Stratagene) and verified by sequencing. To exchange
the backbone vector from retrovirus-based to lentivirus-based, insert
PCR was performed with retroviral pBABE-YAP1 or YAP S127A
plasmid as the template. TA cloning was subsequently performed
using All in OneTM PCR Cloning Kit (Biofact, Daejun, Korea) accord-
ing to the manufacture’s protocol. The multiple independent clones
were isolated and confirmed by DNA sequencing. The correct plas-
mids were subcloned into lentiviral pLVX vector (Takara Bio Inc,
Shimogyo-ku, Kyoto, Japan, cat #632164). The direction of the
ligated fragment was confirmed by restriction mapping using EcoR I
and Xba I enzymes.
Establishment of YAP-overexpressing and YAP silenced stable
cell lines
For stable YAP-overexpressing cells, ectopic expression of empty
control vector (pLVX), wild-type YAP (YAP-WT), or the YAP S127A
mutant (YAP-S127A) in H3122 cell lines was achieved by a lentivi-
ral-based approach. Transfection of lentiviral vectors together with
lentiviral packaging mixtures into HEK293T cells (ATCC) was
performed using lipofectamine 3000 reagent (Invitrogen, Carlsbad,
CA) according to manufacturer’s instructions. At 48 h post-transfec-
tion, the resulting lentiviral supernatant was collected and further
filtered through a 0.45-lm pore filter and used to infect cells in the
presence of 10 lg/ml polybrene. The transduced cells were then
selected with 10 lg/ml puromycin to establish cells stably express-
ing YAP or YAP-S127A. For stable YAP knockdown cells, lentiviral
particles for YAP shRNA (sc-38637-V; Santa Cruz Biotechnology,
Dallas, TX) and control shRNA (sc-108080; Santa Cruz Biotechnol-
ogy) were applied with 5 lg/ml polybrene to 60–70% confluent
cells according to manufacturer’s instructions.
Animal studies
All animal experiments were performed in compliance with world-
wide standard animal care conditions by the Institutional Animal
Care and Use Committee at Yonsei University College of Medicine.
The research proposal was approved by the Association for Assess-
ment and Accreditation of Laboratory Animal Care. Mice cages were
limited to maximum of five animals per cage and checked daily for
cage cleanliness and sufficient food/water.
We performed two types of in vivo studies using tumor xenograft
models. To test the anti-tumor effect of statins in CR pool cell-
derived xenografts, 6- to 8-week-old female nude mice (OrientBio,
Seoul, Korea) were used and tumor xenograft models were generated
by subcutaneous injection of 5 × 106 cells/0.1 ml PBS. Mice were
randomly grouped (n = 6 mice per group) when tumors volume
reached 150–200 mm3 and received the following treatments:
vehicle, crizotinib (Crizo, 50 mg/kg, oral daily), cerivastatin
(Cerivas, 1 mg/kg, intraperitoneal [i.p.] injection daily), atorvastatin
(ATO, 10 mg/kg, i.p. daily) verteporfin (VP, 10 mg/kg, i.p. every
2 days) and combinations of Crizo with either Cerivas, ATO, or VP.
For in vivo tumorigenicity experiments, H3122 parental cell lines
expressing YAP-WT or YAP-S127A (5 × 106 cells/0.1 ml PBS for
each cell line) were subcutaneously injected into the right flank of
nude mice. pLVX cells with control vectors were injected into the
left flank of the same mice. We then measured and documented
tumor size every 3 days until tumors appeared, and monitored for a
further 3 weeks after tumor volume reached 40–50 mm3. Similarly,
CR pool cells expressing control shRNA or YAP shRNA
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(5 × 106 cells/0.1 ml PBS for each cell line) were subcutaneously
injected into the left or right flank of nude mice, and tumor inci-
dence was evaluated. Tumor volumes were measured twice a week
to evaluate tumor growth rate, which was calculated using the
formula: 0.532 × length × width2. % change in tumor volume was
calculated according to the following formula: (Vt  V0)/V0 × 100.
TGI was calculated using the method of Drilon et al (2018):
100% × [1  (TVt  TV0)/(CVt  CV0)] where V0 was the tumor
volume at the beginning of the study, Vt was the tumor volume at
the end of the study, TV0 was the V0 in the treatment group, TVt
was the Vt in the treatment, CV0 was the V0 in the control group,
and CVt was the Vt in the control group.
Immunohistochemistry
Following deparaffinization, immunohistochemistry (IHC) was
performed following standard techniques. Briefly, sections were
incubated in 3% H2O2 for 10 min after boiling in Tris–EDTA antigen
retrieval buffers, blocked in 10% normal donkey serum, and incu-
bated overnight at 4°C with primary antibody against human YAP
antigens (Cell Signaling, Technology, Danvers, MA). The sections
were washed and incubated with a biotinylated donkey anti-rabbit
IgG (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA)
for 60 min and then visualized using the ImmunoCruz ABC Stain-
ing System (Santa Cruz Biotechnology). The sections were lightly
counterstained by hematoxylin and then dehydrated with alcohol
and xylene The IHC evaluation was scored using following criteria:
the YAP staining intensity (a scale from 0 to 3 was used, where 0 is
negative, 1 is weak, 2 is moderate, and 3 is strong staining) and
nuclear localization (the percentage of tumor cell nuclei-stained,
where 0 is negative, 1 is < 10%, 2 is 10–50%, and 3 is > 50% of
tumor cell nuclei-stained). All evaluations were independently
reviewed by a pathologist (SHS) in a blinded manner. Antibodies
are listed in Appendix Table S4.
Generation of the crizotinib-resistant PDX model
ALK-positive PDX model (YHIM-1001) was established as previously
described (Kang et al, 2018). For subcutaneous implantation of
tumor tissues, 6-week-old female immunodeficient NOD/Shi-scid
IL2rc null (NOG) mice were used. We generated crizotinib-acquired-
resistant PDX (YHIM-1001CR) by following a modified protocol of
the technique described by Friboulet et al (2014). Briefly, YHIM-
1001 tumor-bearing nude mice were treated with increasing concen-
trations of crizotinib (50, 100, and 150 mg/kg) in a stepwise manner
until tumors were no longer responsive to crizotinib. Tumors that
continued to grow under 150 mg/kg crizotinib were isolated and
transplanted into nude mice again followed by the treatment with
vehicle or crizotinib. The mice were considered resistant to crizotinib
if tumors continued to grow under 150 mg/kg crizotinib treatment.
In vivo YAP studies in conditional EML4-ALK transgenic mice
We have previously produced conditional EML4-ALK transgenic
mice (Pyo et al, 2017; Yun et al, 2018). Briefly, 6-week-old male
SPC-Cre-ERT2/EML4-ALK transgenic mice were treated with tamox-
ifen to induce EML4-ALK-mediated lung cancer. The mice were
treated with either crizotinib (150 mg/kg orally) or ceritinib
(75 mg/kg orally), and magnetic resonance imaging (MRI) was
performed to monitor the tumor response. Mice showed complete
response to crizotinib or ceritinib within 2 weeks of treatment, but
continued treatment led to disease progression.
Tumor biopsy samples
All patient tumor biopsy samples were obtained from patients with
ALK rearrangements before and after treatment with ALK-TKIs at
the Yonsei University Severance Hospital (Republic of Korea), the
National University Cancer Institute (Singapore), and the National
Taiwan University Hospital (Taiwan). The study protocol was
approved by the Institutional Review Board of each Institute.
Informed consent was obtained for all patients, and experiments
were conformed to the principles set out in the World Medical Asso-
ciation Declaration of Helsinki and the United States Department of
Health and Human Services Belmont Report.
Sequencing of patient samples
All available post-treatment biopsy samples were analyzed for ALK
mutations conferring drug resistance. Testing was performed using
the Ion AmpliseqTM hotspot cancer panel, which includes 50 cancer-
related genes, including ALK. Tumor genomic DNA was extracted
from formalin-fixed, paraffin-embedded (FFPE) tumor tissue blocks,
and the library was prepared. The pooled capture library was quan-
tified using Qubit (Invitrogen) and Tape Station (Agilent Technolo-
gies, Santa Clara, CA) and sequenced with an Ion ProtonTM System.
Sequencing data and ALK-resistant mutations were processed and
reported as previously described (Gainor et al, 2016).
Statistical analysis
Statistical analysis was performed using Mann–Whitney test for
comparisons of two groups or by Kruskal–Wallis with Dunn’s post
hoc test or ANOVA with Tukey’s post hoc test for comparisons of
multiple groups, appropriately. Computations were performed using
SPSS and GraphPad Prism software. Cell line experiments were
independently repeated more than three times, with technical tripli-
cate in each condition. For animal studies, the mice were randomly
grouped when a tumor reached 200 mm3 size before drug treat-
ment. Tumor growth was measured by two individuals indepen-
dently. The staining intensity for IHC studies was blindly assessed
by a pathologist. Data in figures are expressed as the means  SD
or  SE for three or more individual experiments. P < 0.05
was considered significant. Exact P-values are included in
Appendix Table S5. All statistical analyses were all reviewed by our
statistical collaborators.
Expanded View for this article is available online.
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